You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Dow
Moodys
Baxter
Express Scripts
Mallinckrodt
AstraZeneca

Last Updated: August 5, 2020

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 077130

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

NDA 077130 describes RIVASTIGMINE TARTRATE, which is a drug marketed by Alembic Pharms Ltd, Apotex Inc, Aurobindo Pharma Ltd, Cadila Pharms Ltd, Chartwell Rx, Dr Reddys Labs Inc, Macleods Pharms Ltd, Orchid Hlthcare, Sun Pharm, and Watson Labs, and is included in ten NDAs. It is available from eleven suppliers. Additional details are available on the RIVASTIGMINE TARTRATE profile page.

The generic ingredient in RIVASTIGMINE TARTRATE is rivastigmine tartrate. There are thirty-two drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the rivastigmine tartrate profile page.
Summary for 077130
Tradename:RIVASTIGMINE TARTRATE
Applicant:Dr Reddys Labs Inc
Ingredient:rivastigmine tartrate
Patents:0
Formulation / Manufacturing:see details
Pharmacology for NDA: 077130
Mechanism of ActionCholinesterase Inhibitors
Suppliers and Packaging for NDA: 077130
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
RIVASTIGMINE TARTRATE rivastigmine tartrate CAPSULE;ORAL 077130 ANDA Dr. Reddy's Laboratories Limited 55111-352 55111-352-01 100 CAPSULE in 1 BOTTLE (55111-352-01)
RIVASTIGMINE TARTRATE rivastigmine tartrate CAPSULE;ORAL 077130 ANDA Dr. Reddy's Laboratories Limited 55111-352 55111-352-05 500 CAPSULE in 1 BOTTLE (55111-352-05)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrengthEQ 1.5MG BASE
Approval Date:Oct 31, 2007TE:ABRLD:No

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrengthEQ 3MG BASE
Approval Date:Oct 31, 2007TE:ABRLD:No

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrengthEQ 4.5MG BASE
Approval Date:Oct 31, 2007TE:ABRLD:No

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Colorcon
Mallinckrodt
AstraZeneca
Johnson and Johnson
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.